Difference between revisions of "SYSTEMIC SCLEROSIS-LUNGS"
(Imported from text file) |
(Imported from text file) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
===== [[Summary Article|'''SUMMARY''']] ===== | ===== [[Summary Article|'''SUMMARY''']] ===== | ||
1. Main cause of morbidity/mortality in SSC, lung death is due to pulmonary HTN | 1. Main cause of morbidity/mortality in SSC, lung death is due to pulmonary HTN: arterial intimal proliferation & interstitial fibrosis. | ||
<br/> | <br/> | ||
<br/>2. Order pulmonary function tests (PFTs) with spirometry regularly (every 6-12 months). | <br/>2. Order pulmonary function tests (PFTs) with spirometry regularly (every 6-12 months). | ||
| Line 12: | Line 12: | ||
==Reference(s)== | ==Reference(s)== | ||
Wilkinson, I. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. | Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.] | ||
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.] | |||
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | <br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy. | ||
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | <br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021]. | ||
Latest revision as of 11:07, 20 March 2023
SUMMARY
1. Main cause of morbidity/mortality in SSC, lung death is due to pulmonary HTN: arterial intimal proliferation & interstitial fibrosis.
2. Order pulmonary function tests (PFTs) with spirometry regularly (every 6-12 months).
3. Cyclophosphamide may be used for interstitial lung disease with active alveolitis.
4. Pulmonary HTN is often treated with drugs that cause vasodilation of the pulmonary vasculature such as prostaglandins.
5. Lung transplant may be required.
Reference(s)
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
